Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Wiseman

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
American Journal of Human Genetics|July 24, 2004
A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD StudyElizabeth R Hauser, David C Crossman, Christopher B Granger, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Blood|September 7, 2014
Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)Pranesh K Chakraborty, Klaus Schmitz-Abe, Erin K Kennedy, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Hemasphere|May 17, 2024
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortiumCristina A Tentori, Lin P Zhao, Benedetta Tinterri, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
American Journal of Human Genetics|July 24, 2004
A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD StudyElizabeth R Hauser, David C Crossman, Christopher B Granger, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Blood|September 7, 2014
Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)Pranesh K Chakraborty, Klaus Schmitz-Abe, Erin K Kennedy, et al.
Bone Marrow Transplantation|April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committeeChristopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
The Lancet. Haematology|June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCarmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.
Hemasphere|May 17, 2024
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortiumCristina A Tentori, Lin P Zhao, Benedetta Tinterri, et al.
Pageof 16